Fewer people under age 50 are dying from cancer in the U.S., but colorectal cancer mortality rates continue to surge ...

Multiple myeloma is the second most common blood cancer in the United States, and it is more common in men, with an estimated ...

CARY, NC, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- The CEO Roundtable on Cancer (CEORT) today announced ...

Researchers at Moffitt Cancer Center have developed a new way to predict how cancer cells evolve by gaining and losing whole ...

Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells ...

And so we really need more research into how to optimize these patients long-term, especially when we generally do not use menopausal hormone therapy in hormone receptor positive breast cancer.

At the San Antonio Breast Cancer Symposium in 2025. We saw the results of the lidERA study, which looked at the oral SERD ...

A molecule produced by cancer cells can shield the brain from Alzheimer’s disease in mice. For decades, researchers have ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.

Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy found that ...

Janux will conduct preclinical studies of the undisclosed program targeting a validated solid tumor antigen expressed across several cancer types.

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...